Zilico is to launch its pioneering newly CE marked cervical cancer diagnostics system at Medica 2013.
The British company’s innovative system, ZedScan I, which recently received EC certification from its notified body, offers more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management.
The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result.
ZedScan offers clinical benefits by identifying those patients who require treatment at first visit, facilitating a wider use of ‘Select & Treat’ in addition to reducing the number of cervical biopsies performed on each patient by pinpointing the optimum site for biopsy.
Zilico’s patented Electrical Impedance Spectroscopy (EIS) technology exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue.
The system, which is both safe and painless, consists of a portable hand-held device and docking station, software application and a single-use EIS sensor.
Five clinical trials in the UK and EU have supported the clinical efficacy of ZedScan, including a pivotal European trial of 429 women in 2011 across three hospitals in the UK and Ireland.
Following EC certification, ZedScan is being introduced into a number of clinics in the UK and healthcare systems across the globe.
Sameer Kothari, chief executive of Zilico, said: “ZedScan has generated substantial interest from distributors across the globe through various presentations, conferences and clinical meetings and we now look forward to being able to satisfy the growing demand.”